| Overview |
| bs-7970R |
| ARS2 Polyclonal Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Rat |
| Human, Mouse, Dog, Cow, Pig, Horse |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human ARS2 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 51593 |
| Cytoplasm, Nucleus |
| ARS2 protein; Arsenate resistance protein ARS2; Arsenite resistance protein 2; Arsenite resistance protein; ASR2; MGC126427; Serrate; Serrate RNA effector molecule homolog Arabidopsis; Serrate RNA effector molecule homolog; SRRT; SRRT_HUMAN. |
| ARS2(Arsenite resistance protein 2) confers arsenite resistance. The protein belongs to the ARS2 family. Arsenic is a human carcinogen whose mechanism of action is unknown. The arsenite acts as a comutagen by interfering with DNA repair. Two genes, ASR1(Arsenite resistance protein 1) and ASR2 (Arsenite resistance protein 2), confer arsenite resistance to arsenite-sensitive cells. ASR1 shows almost complete homology with the rat fau gene, a tumor suppressor gene which contains a ubiquitin like region fused to S30 ribosomal protein. Arsenite inhibits ubiquitin dependent proteolysis. The tumor suppressor fau gene product or some other aspect of the ubiquitin system may be a target for arsenic toxicity and that disruption of the ubiquitin system may contribute to the genotoxicity and carcinogenicity of arsenite. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz